Addition of spironolactone in patients with resistant arterial
hypertension (ASPIRANT): a randomized, double-blind,
placebo-controlled trial

J 2011

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

VÁCLAVÍK, Jan; Richard SEDLAK; Martin PLACHY; Karel NAVRATIL; Jiří PLASEK et al.

Základní údaje

Originální název

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

Autoři

VÁCLAVÍK, Jan; Richard SEDLAK; Martin PLACHY; Karel NAVRATIL; Jiří PLASEK; Jiří JARKOVSKÝ ; Tomáš VACLAVIK; Roman HUSAR; Eva KOCIANOVA a Miloš TABORSKY

Vydání

HYPERTENSION, 2011, 0194-911X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 6.207

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00055476

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1161/HYPERTENSIONAHA.111.169961

UT WoS

000290710800017

Klíčová slova anglicky

resistant hypertension; spironolactone; clinical trials; blood pressure; ambulatory blood pressure monitoring

Příznaky

Mezinárodní význam

Změněno: 9. 2. 2012 07:27, Mgr. Michal Petr

Anotace

V originále

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95%CI -10.0; -0.8) for systolic BP (P=0.024) and -1.0 mm Hg (95% CI -4.0; 2.0) for diastolic BP (P=0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of -8.6, -9.8, and -6.5 mm Hg; P=0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (-3.0, -1.0, and -2.5 mm Hg; P=0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.

Citovat

VÁCLAVÍK, Jan; Richard SEDLAK; Martin PLACHY; Karel NAVRATIL; Jiří PLASEK; Jiří JARKOVSKÝ; Tomáš VACLAVIK; Roman HUSAR; Eva KOCIANOVA a Miloš TABORSKY. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. HYPERTENSION. 2011, roč. 57, č. 6, s. 1069-1075. ISSN 0194-911X. Dostupné z: https://doi.org/10.1161/HYPERTENSIONAHA.111.169961.

@article{970396,
   author = {Václavík, Jan and Sedlak, Richard and Plachy, Martin and Navratil, Karel and Plasek, Jiří and Jarkovský, Jiří and Vaclavik, Tomáš and Husar, Roman and Kocianova, Eva and Taborsky, Miloš},
   article_number = {6},
   doi = {https://doi.org/10.1161/HYPERTENSIONAHA.111.169961},
   keywords = {resistant hypertension; spironolactone; clinical trials; blood pressure; ambulatory blood pressure monitoring},
   language = {eng},
   issn = {0194-911X},
   journal = {HYPERTENSION},
   title = {Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial},
   volume = {57},
   year = {2011}
}

TY  - JOUR
ID  - 970396
AU  - Václavík, Jan - Sedlak, Richard - Plachy, Martin - Navratil, Karel - Plasek, Jiří - Jarkovský, Jiří - Vaclavik, Tomáš - Husar, Roman - Kocianova, Eva - Taborsky, Miloš
PY  - 2011
TI  - Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial
JF  - HYPERTENSION
VL  - 57
IS  - 6
SP  - 1069-1075
EP  - 1069-1075
SN  - 0194911X
KW  - resistant hypertension
KW  - spironolactone
KW  - clinical trials
KW  - blood pressure
KW  - ambulatory blood pressure monitoring
N2  - There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95%CI -10.0; -0.8) for systolic BP (P=0.024) and -1.0 mm Hg (95% CI -4.0; 2.0) for diastolic BP (P=0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of -8.6, -9.8, and -6.5 mm Hg; P=0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (-3.0, -1.0, and -2.5 mm Hg; P=0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.
ER  -

VÁCLAVÍK, Jan; Richard SEDLAK; Martin PLACHY; Karel NAVRATIL; Jiří PLASEK; Jiří JARKOVSKÝ; Tomáš VACLAVIK; Roman HUSAR; Eva KOCIANOVA a Miloš TABORSKY. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. \textit{HYPERTENSION}. 2011, roč.~57, č.~6, s.~1069-1075. ISSN~0194-911X. Dostupné z: https://doi.org/10.1161/HYPERTENSIONAHA.111.169961.

Přehled o publikaci